Daily Cardiology Research Analysis
Analyzed 281 papers and selected 3 impactful papers.
Summary
Three studies advance cardiology across diagnostics, epidemiology, and structural intervention. A lipid-capped transistor assay achieved early, multiplexed AMI biomarker detection with high accuracy, potentially enabling earlier prehospital triage. A population-based cohort showed long COVID is linked to increased incident cardiovascular disease, while a decade-long comparison of TAVR versus SAVR in patients <70 years found similar hard outcomes but higher reintervention after TAVR.
Research Themes
- Rapid, multiplexed point-of-care diagnostics for acute myocardial infarction
- Cardiovascular risk after long COVID in community-managed populations
- Long-term comparative effectiveness of TAVR versus SAVR in younger patients
Selected Articles
1. A transistor-based point-of-care assay with lipid-capped sensory interface for clinical profiling of cardiovascular diseases.
This study introduces a lipid-capped transistor assay that simultaneously measures five myocardial injury biomarkers with pg/mL sensitivity, preserving signal quality in human serum. It identified AMI earlier than conventional assays in animal models and achieved 91.7% accuracy for AMI and 79.6% for broader CVD profiling across 265 clinical samples.
Impact: By overcoming Debye screening and non-specific adsorption, this assay enables earlier, multiplexed AMI detection with strong clinical sample performance, addressing a key bottleneck in prehospital diagnosis.
Clinical Implications: If validated prospectively, this platform could accelerate early AMI triage outside hospitals, support rule-in/rule-out decisions, and enable dynamic risk stratification through multiplex biomarker trajectories.
Key Findings
- Self-assembled phospholipid capping reduced Debye screening and non-specific adsorption, maintaining high sensitivity and specificity in human serum.
- Simultaneous five-biomarker detection achieved pg/mL-level limits and identified AMI 15–45 minutes after injury onset in animals, >30 minutes earlier than biochemical assays.
- Across 265 clinical sera, accuracy was 91.7% for AMI identification and 79.6% for broader CVD classification.
Methodological Strengths
- Multiplexed detection of five myocardial biomarkers with quantitative accuracy in human serum
- Demonstrated earlier detection window versus standard biochemical assays and validated in 265 clinical samples
Limitations
- Single-platform study without multicenter prospective validation or outcome linkage
- Workflow and robustness in real-world prehospital settings remain untested
Future Directions: Prospective, multicenter diagnostic accuracy and clinical utility trials comparing standard-of-care pathways; integration with EMS workflows; evaluation of time-to-treatment and outcomes.
Point-of-care (POC) testing for electrical detection of cardiovascular disease (CVD) can enable effective screening and surveillance. However, the complexity and diversity of serum samples interfere with the transduction of electrical signals, limiting the sensitivity and accuracy of the biochemical assay. Here, we present the development and performance of an electrical POC assay based on self-assembled lipid-capped transistor sensory interfaces for the simultaneous detection and profiling of five myocardial injury biomarkers, with detection limits as low as pg/mL levels. By reducing Debye screening and non-specific adsorption through phospholipid self-assembly, the electrical assay maintains high sensitivity and specificity in human serum, as well as promising quantitative accuracy. For acute myocardial infarction (AMI) animal modeling, our assay detects variations in key biomarker characteristics within 15 to 45 min after the onset of myocardial injury, with a detection time window more than 30 min earlier than biochemical assays. Through the combination profiling of five biomarker signatures from 265 clinical serum samples, our assay achieves 91.7% accuracy for AMI identification and 79.6% accuracy for cardiovascular disease classification, effectively monitoring the prognosis of AMI patients. This assay may provide reliable clinical guidance for the early diagnosis, risk assessment, and prognosis monitoring of CVD.
2. Long COVID and risk of incident cardiovascular disease: a prospective cohort study using the Multimorbidity Integrated Registry Across Care Levels in Stockholm (MIRACLE-S) cohort.
In a population-based cohort of 1.2 million adults, physician-diagnosed long COVID was independently associated with higher incident cardiovascular disease, especially arrhythmias, coronary disease, and—in women—heart failure and peripheral artery disease; stroke risk was not elevated.
Impact: Provides robust, population-level evidence that long COVID confers excess cardiovascular risk in community-managed individuals, informing surveillance and preventive strategies.
Clinical Implications: Clinicians should incorporate long COVID status into cardiovascular risk assessment, prioritize rhythm monitoring and evaluation for heart failure/CAD, and consider sex-specific surveillance strategies.
Key Findings
- Long COVID was associated with an adjusted HR of 2.06 (women) and 1.33 (men) for composite cardiovascular outcomes.
- Strongest associations were observed for arrhythmias (women HR 3.11; men HR 1.61) and coronary artery disease (≈1.25 in both sexes).
- Heart failure and peripheral artery disease risks increased in women; no association with stroke was observed.
Methodological Strengths
- Large, population-based registry covering all care levels with rigorous exclusions and covariate adjustment
- Sex-stratified analyses and comprehensive composite outcomes
Limitations
- Observational design with potential residual confounding and diagnostic coding biases
- Exposure misclassification and lack of granular pathophysiologic markers
Future Directions: Mechanistic studies to elucidate post-viral pathways; trials of screening/monitoring strategies; evaluation of interventions mitigating arrhythmia and heart failure risk after long COVID.
BACKGROUND: Long COVID has emerged as a global health challenge, with increasing evidence of cardiovascular sequelae. Most previous studies have focused on hospitalised cohorts, whereas cardiovascular risk in community-managed long COVID cases remains less explored. We aimed to investigate the incidence of major cardiovascular events in individuals with long COVID compared to those without long COVID in a large population-based setting. METHODS: Multimorbidity Integrated Registry Across Care Levels in Stockholm (MIRACLE-S) is a population-based cohort that covers all providers of healthcare for around 2.5 million residents in Stockholm County. Individuals aged 18-65 years with a physician-assigned long COVID diagnosis (ICD-10: U09.9) between October 2020 and January 2025 were identified. Exclusion criteria were hospitalisation for acute COVID-19 or pre-existing cardiovascular disease. Cox proportional hazards models estimated the effect of long COVID on a composite cardiovascular outcome (myocardial infarction, heart failure, cardiac arrhythmias, stroke, peripheral arterial disease), adjusting for demographic, lifestyle, and mental health factors. FINDINGS: Among 1,217,693 individuals, 8999 (0.7%) had long COVID diagnosis (66% women). Cumulative incidence of any cardiovascular event was higher in long COVID group (women 18.2%, men 20.6%) compared with control group (women 8.4%, men 11.1%). In a fully adjusted model, long COVID was associated with the composite cardiovascular outcome (women HR 2.06, 95% CI 1.92-2.22; men HR 1.33, 1.20-1.48), cardiac arrhythmia (women HR 3.11, 2.85-3.39; men HR 1.61, 1.41-1.85), and coronary artery disease (women HR 1.25, 1.04-1.52; men HR 1.26, 1.05-1.51). Heart failure incidence was elevated in women only (HR 1.25, 1.00-1.55), as also was peripheral artery disease (HR 1.25, 1.05-1.50). Long COVID was not associated with stroke in either sex. INTERPRETATION: Long COVID is associated with increased risk of incident cardiovascular disease, particularly cardiac arrhythmias, heart failure, and coronary artery disease. These findings underscore the need for systematic follow-up and integration of long COVID into cardiovascular risk assessment. FUNDING: Region Stockholm and Heart Lung Foundation.
3. Long-term follow-up of surgical versus transcatheter aortic valve replacement in patients younger than 70 years.
In propensity-matched patients <70 years, TAVR and SAVR showed similar long-term rates of all-cause death, stroke, and rehospitalization up to 10 years, but TAVR had higher reintervention rates without mortality impact.
Impact: Addresses a key evidence gap for younger, low-to-intermediate risk patients, informing device durability and lifetime management planning.
Clinical Implications: For patients <70 years, both TAVR and SAVR achieve comparable major outcomes, but clinicians should counsel about higher reintervention risk with TAVR when planning lifetime valve strategies.
Key Findings
- In matched patients <70 years, the 10-year composite of death, stroke, and valve/procedure-related hospitalization was similar between TAVR and SAVR.
- TAVR was associated with a higher rate and hazard of reintervention over time, without affecting mortality.
- Flexible parametric survival modeling characterized time-varying reintervention risk.
Methodological Strengths
- Propensity score–matched long-term comparison with balanced baseline risk
- Use of flexible parametric survival models to assess time-varying reintervention hazards
Limitations
- Observational design with potential residual confounding and device-era effects
- Sample size reduced after matching, limiting subgroup analyses
Future Directions: Head-to-head randomized trials and registry linkages in younger cohorts to assess valve durability, bioprosthetic failure phenotypes, and patient-reported outcomes.
OBJECTIVE: Transcatheter aortic valve replacement (TAVR) is an established alternative to surgical aortic valve replacement (SAVR) in intermediate- and low-risk patients with severe aortic stenosis. However, most randomized trials have enrolled patients older than 70 years with limited follow-up, and evidence on long-term outcomes in younger populations remains insufficient. Our objective was to compare long-term clinical outcomes between propensity-matched TAVR and SAVR patients aged <70 years. METHODS: A total of 959 patients (SAVR: 808, TAVR: 151) were included, resulting in 132 propensity-matched patients per group. The primary outcome was a composite of all-cause death, stroke, and procedure- or valve-related hospitalization at 30 days, 2 years, 5 years, and up to 10 years. A flexible parametric survival model was used to evaluate the hazard ratio (HR) for reintervention and its time dynamics. RESULTS: Baseline characteristics were balanced between matched groups (mean age 64.9 years; Society of Thoracic Surgeons Predicted Risk of Mortality score 2.9%). At 10 years, primary outcome rates were similar (SAVR: 50.8% vs TAVR: 42.9%; HR, 1.01; 95% CI, 0.66-1.53; CONCLUSIONS: At long-term follow-up, all-cause mortality, stroke, and rehospitalization rates were similar between TAVR and SAVR in patients younger than 70 years with aortic stenosis. However, patients who underwent TAVR had greater rates and risk of reintervention, which did not affect mortality.